Skip to main content

Alentis secures 67 million US dollars

Thomas Baumert, Alentis
| News

Alentis secures 67 million US dollars


The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds will be deployed to develop its pipeline of drugs treating advanced liver and kidney fibrosis.

Thomas Baumert, Alentis
Thomas Baumert, Founder and Executive BoD

Alentis Therapeutics develops anti-fibrotic molecules to treat advanced liver and kidney fibrosis and also, by means of its proprietary platform, works on programs targeting other fibrotic diseases and hepatobiliary cancers.

Now, the Basel-based biotechnology company has secured 67 million US dollars in a series B funding round according to a press release. This will be used to bring Alentis’s lead product, monoclonal antibodies targeting claudin-1through a proof-of-concept study. Professor Thomas Baumert of the University of Strasbourg, who founded Alentis, is quoted in the press release, saying: “Fibrosis is an important risk factor for cancer, and Claudin-1 has a well-established role in cancer biology including tumor invasion and metastasis. Given the absent and unsatisfactory treatment options, it’s critical that we deliver new therapeutics for patients suffering from fibrosis and cancer.”

BaseLaunch, the biotech incubator and accelerator of Basel Area Business & Innovation, provided Alentis with decisive support during its founding phase and helped setting up the company in Basel. The funding round was led by Morningside Venture Investments and joined by Jeito Capital as well as the the Series A investors.

Jason Dinges from Morningside and Rafaèle Tordjman, Founder and CEO of Jeito Capital, have been welcomed to the Board of Directors. “Alentis has an outstanding and experienced team from pharma and biotech and is focused on a unique target, based on the founder’s work and his team of more than 10 years,” Tordjman is quoted as saying in the press release. Alentis Therapeutics plans to start the first clinical trials in Q4 2021.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.